Aptamer Group raises £60,000 via Supplementary Conditional Placing

Aptamer Group

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced that, in addition to the Placing and Subscription announced on 24 July 2024, it has agreed to issue a further 30,000,000 New Ordinary Shares at the same issue price of 0.2p per share, raising £60,000 (before expenses), which will be for working capital purposes.

This additional sum has arisen due to a reconciliation error by the Company’s broker, Turner Pope Investments (TPI) Ltd, relating to client orders received in the Fundraising. Turner Pope noticed this matter yesterday and informed the Company and the Board has agreed to issue the Supplementary Placing Shares.

Notwithstanding the circumstances under which the proposed issue of the Supplementary Placing Shares has arisen, they will not form part of the Fundraising and will be issued as a separate tranche. Both the conditional element of the Fundraising and the Supplementary Placing Shares are subject to shareholder approval of the resolutions at the Company’s General Meeting, which is scheduled for 13 August 2024.

Subject to the passing of the resolutions at the General Meeting, admission of the Supplementary Placing Shares is expected to become effective and dealings are expected to commence at 8.00 a.m. on 14 August 2024.

Total Voting Rights

Immediately following Admission the Company will have 1,920,343,673 ordinary shares of £0.001 each in issue.

Aptamer Group does not hold any shares in treasury and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group reports on significant commercial and technical progress in H1 report

    Aptamer Group plc reports progress on key projects in its H1 2025 trading update, highlighting partnerships with Unilever and Alzheimer's biomarker validation.

    Aptamer Group signs agreement worth up to £155,000

    Aptamer Group plc (LON: APTA) secures a £155,000 contract to develop Optimer® binders for a rare disease biopharma, boosting clinical trial capabilities.

    Aptamer Group appoints three new members to its Scientific Advisory Board

    Aptamer Group plc enhances its Scientific Advisory Board with three leading experts to drive innovation and commercialization in targeted therapy solutions.

    Aptamer advances with Unilever, Alzheimer’s diagnostics and AstraZeneca RNA therapies

    Aptamer Group plc (LON: APTA) updates on strategic programs with Unilever, Neuro-Bio, AstraZeneca, enhancing their Optimer® technology potential.

    Aptamer Group to host webinar and Q&A session for investors

    Join Aptamer Group plc's webinar on Dec 12, 2024, at 6 PM GMT for insights and Q&A with CEO Dr. Arron Tolley and CSO Dr. David Bunka.

    Aptamer Group reports progress in partnerships and growth strategy at AGM

    Aptamer Group plc is set to host its AGM, highlighting progress in cost reduction, commercial growth, and high-profile partnerships in life sciences.

      Search

      Search